4.5 Article

COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA. 2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022

期刊

EUROSURVEILLANCE
卷 27, 期 18, 页码 8-13

出版社

EUR CENTRE DIS PREVENTION & CONTROL
DOI: 10.2807/1560-7917.ES.2022.27.18.2200322

关键词

-

资金

  1. Swedish Research Council (VR) [2019-00198, 2021-04665]
  2. Sweden's Innovation Agency (Vinnova) [2021-02648]
  3. Swedish Research Council
  4. Governmental Funds for Clinical Research (ALF)
  5. Swedish Research Council for Health, Working life and Welfare (Forte) [2020-00962]
  6. Lund University
  7. Formas [2020-00962] Funding Source: Formas
  8. Forte [2020-00962] Funding Source: Forte
  9. Swedish Research Council [2021-04665] Funding Source: Swedish Research Council

向作者/读者索取更多资源

We compared the effectiveness of vaccines against severe COVID-19 during the period of December 2021 to March 2022, when Omicron BA.1 and BA.2 variants were dominant in Scania county, Sweden. The effectiveness remained above 80% for individuals with at least three vaccine doses, but decreased to 54% for those with only two doses. Protection from prior infection was also lower after the transition to BA.2. Booster vaccination appears to be necessary to maintain sufficient protection.
We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine doses but the point estimate decreased markedly to 54% among those with only two doses. Protection from prior infection was also lower after the transition to BA. 2. Booster vaccination seems necessary to maintain sufficient protection.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据